ERBB2 and lung cancer: Afatinib, a TKI targeting both EGFR and ErbB2, in combined with anti-EGFR antibody could remarkably attenuate the ErbB2 signaling and in turn resumed the sensitivity of lung cancer and colorectal cancer to TKIs in vitro and in vivo [45, 46].